LEPR and breast carcinoma: Interestingly, blocking leptin signaling by using a full leptin receptor antagonist, the peptide LDFI [203], completely reversed the breast CSC phenotype [173], further highlighting the potential advantage of targeting leptin signaling to block breast cancer malignancy.